?? CoLab #3 Top Oncology Patent Leaders in 2024, Brazil’s Regulatory Overhaul, AI Tripling Stroke Recovery Rates, and More
?? Hey, there! As we approach the holiday season, we want to spread the cheer. That’s why CoLab #3 is dedicated to the most positive industry news of the last few days—guaranteed to put a smile on your face and restore your feeling of hope.
Here's what’s been on our radar:
?? 1. 2024 oncology patent leaders reflect the industry’s efforts to address unmet cancer needs?
We’re wrapping up 2024 with some good news: the oncology patent landscape highlights a surge in innovation, with top pharma companies focusing on immuno-oncology, personalized medicine, and novel biologics. Emerging players challenge traditional leaders, expanding the global reach (the influence of Asian companies on the market is growing) and showcasing a shift toward targeted patient-centric therapies.
And here’s the ranking:
?? 2. The industry’s projected to grow by 7.7% by 2030. What’s behind the upward trend?
The pharmaceutical industry's projected 7.7% growth rate through 2030 is driven by a shift from niche products to treatments targeting prevalent conditions like obesity, diabetes, and cancer.?
Notably, the obesity market is expected to reach $66 billion by 2030, with incretin-based therapies potentially becoming the first drug class to achieve $100 billion in annual sales. This focus on widespread diseases reflects a strategic move to address significant global health challenges.
?? What does this mean?
A shift away from rare diseases. Over the last decade, niche products’ prescription share doubled from just 10% in 2014. That’s posed to change as pharma focuses on “big diseases”.?
On the level of clinical trials, precision will still be needed for identifying and recruiting eligible patients. Patient access to trial sites remains a priority.
?? 3. Brazil emerging as top clinical trials destination after regulatory overhaul
On December 2, 2024, the Brazilian National Health Surveillance Agency (ANVISA) issued Resolution RDC No. 945/2024, introducing new guidelines for clinical trials aimed at drug marketing authorization in Brazil.?
领英推荐
Effective January 1, 2025, these rules streamline processes by allowing parallel ethical and regulatory submissions, waiving notifications for certain post-marketing and non-interventional studies, and expediting investigational drug imports.?
This regulatory overhaul aims to reduce bureaucratic barriers, aligning with international standards to enhance Brazil's appeal for clinical research.
?? 5. Looking for New Opportunities?
Check out these jobs in clinical research:
?? From 16% to 48% functional independence after stroke thanks to AI adoption
Artificial intelligence (AI) is significantly enhancing health outcomes in England through its integration into stroke care and the regulation of medical devices. As of late 2024, all 107 stroke centers in England have adopted AI technology, leading to faster processing and interpretation of brain scans.?
This advancement reduces treatment times by over 60 minutes and increases the proportion of patients achieving functional independence from 16% to 48%.
Additionally, the Medicines and Healthcare Products Regulatory Agency (MHRA) has initiated the AI Airlock pilot scheme to evaluate AI-powered medical devices. This program aims to ensure the safety and efficacy of AI technologies in healthcare, facilitating their swift and secure integration into the NHS.
These developments underscore AI's transformative potential in improving patient care and health outcomes.
?? Stay Tuned That’s it for this issue. Got any thoughts or questions? Drop them in a comment ??.
??Happy Holidays from the TrialHub team! And stay tuned for CoLab #4—out next year.
?? Dedicated to bringing clinical research closer to patients by improving protocol development and trial planning ??
2 个月Reducing bureaucratic barriers is needed in many aspects of clinical research. So pleased to see Brazil is taking steps toward tackling the issue and I have the feeling many more are to follow.